The power Doppler ultrasonography score from 24 synovial sites or 6 simplified synovial sites, including the metacarpophalangeal joints, reflects the clinical disease activity and level of serum biomarkers in patients with rheumatoid arthritis

Rheumatology

Volumn 50, Issue 5, 2011, Pages 962-965

  Kawashiri, Shin Ya ^a   Kawakami, Atsushi ^a   Iwamoto, Naoki ^a   Fujikawa, Keita ^a   Satoh, Katsuya ^a   Tamai, Mami ^a   Nakamura, Hideki ^a   Okada, Akitomo ^a   Koga, Tomohiro ^a   Yamasaki, Satoshi ^a   Ida, Hiroaki ^b   Origuchi, Tomoki ^a   Eguchi, Katsumi ^a  

^a NAGASAKI UNIVERSITY   (Japan)

^b KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Power Doppler; Rheumatoid arthritis; Ultrasonography; Vascular endothelial growth factor

Indexed keywords

ANGIOGENIC FACTOR; BIOLOGICAL MARKER; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; VASCULOTROPIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CORRELATION ANALYSIS; DIAGNOSTIC IMAGING; DISEASE ACTIVITY; DOPPLER ECHOGRAPHY; FEMALE; HUMAN; MALE; METACARPOPHALANGEAL JOINT; PATIENT MONITORING; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SYNOVIUM; TECHNIQUE;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INDUCING AGENTS; ANKLE JOINT; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; ELBOW JOINT; FEMALE; HUMANS; KNEE JOINT; MALE; MATRIX METALLOPROTEINASE 3; METACARPOPHALANGEAL JOINT; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; SYNOVIAL MEMBRANE; TISSUE INHIBITOR OF METALLOPROTEINASE-1; ULTRASONOGRAPHY, DOPPLER; VASCULAR ENDOTHELIAL GROWTH FACTOR A; WRIST JOINT;

EID: 79955160156     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keq415     Document Type: Article

References (11)

1. Joshua F, Edmonds J, Lassere M. Power Doppler ultrasound in musculoskeletal disease: a systematic review. Semin Arthritis Rheum 2006;36:99-108.
2. Naredo E, Rodríguez M, Campos C et al. Validity, reproducibility, and responsiveness of a twelve-joint simplified power Doppler ultrasonographic assessment of joint inflammation in rheumatoid arthritis. Arthritis Rheum 2008; 59:515-22.
3. Kurosaka D, Hirai K, Nishioka M et al. Clinical significance of serum levels of vascular endothelial growth factor, angiopoietin-1, and angiopoietin-2 in patients with rheumatoid arthritis. J Rheumatol 2010;37:1121-8.
4. Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31:315-24.
5. Aletaha D, Nell VP, Stamm T et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther 2005;7:R796-806.
6. Backhaus M, Burmester GR, Gerber T et al. Working Group for Musculoskeletal Ultrasound in the EULAR Standing Committee on International Clinical Studies including Therapeutic Trials. Guidelines for musculoskeletal ultrasound in rheumatology. Ann Rheum Dis 2001;60: 641-9.
7. Ostergaard M, Peterfy C, Conaghan P et al. OMERACT rheumatoid arthritis magnetic resonance imaging studies: core set of MRI acquisitions, joint pathology definitions, and the OMERACT RA-MRI scoring system. J Rheumatol 2003;30:1385-6.
8. Ram M, Sherer Y, Shoenfeld Y. Matrix metalloproteinase-9 and autoimmune diseases. J Clin Immunol 2006;26:299-307.
9. Tchetverikov I, Ronday HK, Van El B et al. MMP profile in paired serum and synovial fluid samples of patients with rheumatoid arthritis. Ann Rheum Dis 2004;63:881-3.
10. Brown AK, Conaghan PG, Karim Z et al. An explanation for the apparent dissociation between clinical remission and continued structural deterioration in rheumatoid arthritis. Arthritis Rheum 2008;58:2958-67.
11. Naredo E, Möller I, Cruz A et al. Power Doppler ultrasonographic monitoring of response to anti-tumor necrosis factor therapy in patients with rheumatoid arthritis. Arthritis Rheum 2008;58:2248-56.